Low	O
implementation	O
of	O
Xpert	B:C0430022
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
among	O
HIV	O
/	O
tuberculosis	O
co-infected	O
adults	O
in	O
the	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
program	O
.	O

Low	O
implementation	O
of	O
Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
among	O
HIV	B:C0019693
/	O
tuberculosis	O
co-infected	O
adults	O
in	O
the	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
program	O
.	O

Low	O
implementation	O
of	O
Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
among	O
HIV	O
/	O
tuberculosis	B:C0041296
co-infected	O
adults	O
in	O
the	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
program	O
.	O

Low	O
implementation	O
of	O
Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
among	O
HIV	O
/	O
tuberculosis	O
co-infected	B:C0275524
adults	O
in	O
the	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
program	O
.	O

Low	O
implementation	O
of	O
Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
among	O
HIV	O
/	O
tuberculosis	O
co-infected	O
adults	O
in	O
the	O
International	B:C0282574
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
program	O
.	O

Low	O
implementation	O
of	O
Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
among	O
HIV	O
/	O
tuberculosis	O
co-infected	O
adults	O
in	O
the	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	B:C0282574
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
program	O
.	O

Xpert	B:C0430022
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	O
Health	I:C0043237
Organization	I:C0043237
(	O
World	O
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
tuberculosis	O
)	O
diagnostic	O
test	I:C0086143
in	O
individuals	O
suspected	O
of	O
HIV	O
-	O
associated	O
tuberculosis	O
.	O

Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	B:C0043237
Health	I:C0043237
Organization	I:C0043237
(	O
World	O
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
tuberculosis	O
)	O
diagnostic	O
test	I:C0086143
in	O
individuals	O
suspected	O
of	O
HIV	O
-	O
associated	O
tuberculosis	O
.	O

Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	O
Health	I:C0043237
Organization	I:C0043237
(	O
World	B:C0043237
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
tuberculosis	O
)	O
diagnostic	O
test	I:C0086143
in	O
individuals	O
suspected	O
of	O
HIV	O
-	O
associated	O
tuberculosis	O
.	O

Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	O
Health	I:C0043237
Organization	I:C0043237
(	O
World	O
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	B:C0041296
(	O
tuberculosis	O
)	O
diagnostic	O
test	I:C0086143
in	O
individuals	O
suspected	O
of	O
HIV	O
-	O
associated	O
tuberculosis	O
.	O

Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	O
Health	I:C0043237
Organization	I:C0043237
(	O
World	O
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
tuberculosis	B:C0041296
)	O
diagnostic	O
test	I:C0086143
in	O
individuals	O
suspected	O
of	O
HIV	O
-	O
associated	O
tuberculosis	O
.	O

Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	O
Health	I:C0043237
Organization	I:C0043237
(	O
World	O
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
tuberculosis	O
)	O
diagnostic	B:C0086143
test	I:C0086143
in	O
individuals	O
suspected	O
of	O
HIV	O
-	O
associated	O
tuberculosis	O
.	O

Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	O
Health	I:C0043237
Organization	I:C0043237
(	O
World	O
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
tuberculosis	O
)	O
diagnostic	O
test	I:C0086143
in	O
individuals	B:C0237401
suspected	O
of	O
HIV	O
-	O
associated	O
tuberculosis	O
.	O

Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	O
Health	I:C0043237
Organization	I:C0043237
(	O
World	O
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
tuberculosis	O
)	O
diagnostic	O
test	I:C0086143
in	O
individuals	O
suspected	O
of	O
HIV	B:C0019693
-	O
associated	O
tuberculosis	O
.	O

Xpert	O
MTB	I:C0430022
/	I:C0430022
RIF	I:C0430022
is	O
recommended	O
by	O
the	O
World	O
Health	I:C0043237
Organization	I:C0043237
(	O
World	O
Health	I:C0043237
Organization	I:C0043237
)	O
as	O
the	O
initial	O
tuberculosis	O
(	O
tuberculosis	O
)	O
diagnostic	O
test	I:C0086143
in	O
individuals	O
suspected	O
of	O
HIV	O
-	O
associated	O
tuberculosis	B:C0041296
.	O

We	O
sought	O
to	O
evaluate	B:C0220825
field	O
implementation	O
of	O
Xpert	O
among	O
a	O
cohort	O
of	O
HIV	O
/	O
tuberculosis	O
co-infected	O
individuals	O
,	O
including	O
availability	O
,	O
utilization	O
and	O
outcomes	O
.	O

We	O
sought	O
to	O
evaluate	O
field	O
implementation	O
of	O
Xpert	B:C0430022
among	O
a	O
cohort	O
of	O
HIV	O
/	O
tuberculosis	O
co-infected	O
individuals	O
,	O
including	O
availability	O
,	O
utilization	O
and	O
outcomes	O
.	O

We	O
sought	O
to	O
evaluate	O
field	O
implementation	O
of	O
Xpert	O
among	O
a	O
cohort	B:C0599755
of	O
HIV	O
/	O
tuberculosis	O
co-infected	O
individuals	O
,	O
including	O
availability	O
,	O
utilization	O
and	O
outcomes	O
.	O

We	O
sought	O
to	O
evaluate	O
field	O
implementation	O
of	O
Xpert	O
among	O
a	O
cohort	O
of	O
HIV	B:C0019693
/	O
tuberculosis	O
co-infected	O
individuals	O
,	O
including	O
availability	O
,	O
utilization	O
and	O
outcomes	O
.	O

We	O
sought	O
to	O
evaluate	O
field	O
implementation	O
of	O
Xpert	O
among	O
a	O
cohort	O
of	O
HIV	O
/	O
tuberculosis	B:C0041296
co-infected	O
individuals	O
,	O
including	O
availability	O
,	O
utilization	O
and	O
outcomes	O
.	O

We	O
sought	O
to	O
evaluate	O
field	O
implementation	O
of	O
Xpert	O
among	O
a	O
cohort	O
of	O
HIV	O
/	O
tuberculosis	O
co-infected	B:C0275524
individuals	O
,	O
including	O
availability	O
,	O
utilization	O
and	O
outcomes	O
.	O

We	O
sought	O
to	O
evaluate	O
field	O
implementation	O
of	O
Xpert	O
among	O
a	O
cohort	O
of	O
HIV	O
/	O
tuberculosis	O
co-infected	O
individuals	B:C0237401
,	O
including	O
availability	O
,	O
utilization	O
and	O
outcomes	O
.	O

Observational	O
cohort	O
study	O
(	O
patient	B:C0586019
-	I:C0586019
level	I:C0586019
data	I:C0586019
)	O
and	O
cross-sectional	O
study	I:C0010362
(	O
site	O
-	O
level	O
Xpert	O
availability	O
data	O
)	O
.	O

Observational	O
cohort	O
study	O
(	O
patient	O
-	I:C0586019
level	I:C0586019
data	I:C0586019
)	O
and	O
cross-sectional	B:C0010362
study	I:C0010362
(	O
site	O
-	O
level	O
Xpert	O
availability	O
data	O
)	O
.	O

Observational	O
cohort	O
study	O
(	O
patient	O
-	I:C0586019
level	I:C0586019
data	I:C0586019
)	O
and	O
cross-sectional	O
study	I:C0010362
(	O
site	O
-	O
level	O
Xpert	B:C0430022
availability	O
data	O
)	O
.	O

Data	O
were	O
collected	O
at	O
30	O
participating	O
International	B:C0282574
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
sites	O
in	O
18	O
countries	O
from	O
January	O
2012	O
-	O
January	O
2016	O
.	O

Data	O
were	O
collected	O
at	O
30	O
participating	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	B:C0282574
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
sites	O
in	O
18	O
countries	O
from	O
January	O
2012	O
-	O
January	O
2016	O
.	O

Data	O
were	O
collected	O
at	O
30	O
participating	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
sites	B:C0205145
in	O
18	O
countries	O
from	O
January	O
2012	O
-	O
January	O
2016	O
.	O

Data	O
were	O
collected	O
at	O
30	O
participating	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
(	O
International	O
epidemiologic	I:C0282574
Databases	I:C0282574
to	I:C0282574
Evaluate	I:C0282574
AIDS	I:C0282574
)	O
sites	O
in	O
18	O
countries	B:C0454664
from	O
January	O
2012	O
-	O
January	O
2016	O
.	O

All	O
patients	O
were	O
HIV	B:C0019693
-	I:C0019693
infected	I:C0019693
and	O
diagnosed	O
with	O
tuberculosis	O
,	O
either	O
bacteriologically	O
or	O
clinically	O
,	O
and	O
followed	O
until	O
a	O
determination	O
of	O
tuberculosis	O
treatment	O
outcome	O
.	O

All	O
patients	O
were	O
HIV	O
-	I:C0019693
infected	I:C0019693
and	O
diagnosed	B:C0011900
with	O
tuberculosis	O
,	O
either	O
bacteriologically	O
or	O
clinically	O
,	O
and	O
followed	O
until	O
a	O
determination	O
of	O
tuberculosis	O
treatment	O
outcome	O
.	O

All	O
patients	O
were	O
HIV	O
-	I:C0019693
infected	I:C0019693
and	O
diagnosed	O
with	O
tuberculosis	B:C0041296
,	O
either	O
bacteriologically	O
or	O
clinically	O
,	O
and	O
followed	O
until	O
a	O
determination	O
of	O
tuberculosis	O
treatment	O
outcome	O
.	O

All	O
patients	O
were	O
HIV	O
-	I:C0019693
infected	I:C0019693
and	O
diagnosed	O
with	O
tuberculosis	O
,	O
either	O
bacteriologically	O
or	O
clinically	O
,	O
and	O
followed	O
until	O
a	O
determination	O
of	O
tuberculosis	B:C0041296
treatment	O
outcome	O
.	O

We	O
used	O
multivariable	B:C0034980
modified	I:C0034980
Poisson	I:C0034980
regression	I:C0034980
to	O
estimate	O
adjusted	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
for	O
unfavorable	O
tuberculosis	O
treatment	O
outcomes	O
.	O

We	O
used	O
multivariable	O
modified	I:C0034980
Poisson	I:C0034980
regression	I:C0034980
to	O
estimate	O
adjusted	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
for	O
unfavorable	O
tuberculosis	B:C0041296
treatment	O
outcomes	O
.	O

Most	O
sites	B:C0205145
(	O
63	O
%	O
)	O
had	O
access	O
to	O
Xpert	O
,	O
either	O
in	O
the	O
clinic	O
(	O
13	O
%	O
)	O
,	O
in	O
the	O
same	O
facility	O
(	O
20	O
%	O
)	O
or	O
offsite	O
(	O
30	O
%	O
)	O
.	O

Most	O
sites	O
(	O
63	O
%	O
)	O
had	O
access	B:C0444454
to	O
Xpert	O
,	O
either	O
in	O
the	O
clinic	O
(	O
13	O
%	O
)	O
,	O
in	O
the	O
same	O
facility	O
(	O
20	O
%	O
)	O
or	O
offsite	O
(	O
30	O
%	O
)	O
.	O

Most	O
sites	O
(	O
63	O
%	O
)	O
had	O
access	O
to	O
Xpert	B:C0430022
,	O
either	O
in	O
the	O
clinic	O
(	O
13	O
%	O
)	O
,	O
in	O
the	O
same	O
facility	O
(	O
20	O
%	O
)	O
or	O
offsite	O
(	O
30	O
%	O
)	O
.	O

Most	O
sites	O
(	O
63	O
%	O
)	O
had	O
access	O
to	O
Xpert	O
,	O
either	O
in	O
the	O
clinic	B:C0442592
(	O
13	O
%	O
)	O
,	O
in	O
the	O
same	O
facility	O
(	O
20	O
%	O
)	O
or	O
offsite	O
(	O
30	O
%	O
)	O
.	O

Most	O
sites	O
(	O
63	O
%	O
)	O
had	O
access	O
to	O
Xpert	O
,	O
either	O
in	O
the	O
clinic	O
(	O
13	O
%	O
)	O
,	O
in	O
the	O
same	O
facility	O
(	O
20	O
%	O
)	O
or	O
offsite	B:C3828730
(	O
30	O
%	O
)	O
.	O

Among	O
2722	O
HIV	B:C0019693
/	O
tuberculosis	O
patients	O
included	O
,	O
median	O
age	O
was	O
35.4	O
years	O
and	O
41	O
%	O
were	O
female	O
;	O
BMI	O
and	O
CD4	O
count	I:C1277791
were	O
low	O
.	O

Among	O
2722	O
HIV	O
/	O
tuberculosis	B:C0041296
patients	O
included	O
,	O
median	O
age	O
was	O
35.4	O
years	O
and	O
41	O
%	O
were	O
female	O
;	O
BMI	O
and	O
CD4	O
count	I:C1277791
were	O
low	O
.	O

Among	O
2722	O
HIV	O
/	O
tuberculosis	O
patients	O
included	O
,	O
median	O
age	O
was	O
35.4	O
years	O
and	O
41	O
%	O
were	O
female	O
;	O
BMI	B:C1305855
and	O
CD4	O
count	I:C1277791
were	O
low	O
.	O

Among	O
2722	O
HIV	O
/	O
tuberculosis	O
patients	O
included	O
,	O
median	O
age	O
was	O
35.4	O
years	O
and	O
41	O
%	O
were	O
female	O
;	O
BMI	O
and	O
CD4	B:C1277791
count	I:C1277791
were	O
low	O
.	O

Overall	O
,	O
most	O
patients	O
(	O
76	O
%	O
)	O
received	O
at	O
least	O
one	O
TB	B:C2242734
test	I:C2242734
;	O
45	O
%	O
were	O
positive	O
.	O

Overall	O
,	O
most	O
patients	O
(	O
76	O
%	O
)	O
received	O
at	O
least	O
one	O
TB	O
test	I:C2242734
;	O
45	O
%	O
were	O
positive	B:C1446409
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	B:C0430022
:	O
64	O
%	O
were	O
Xpert	O
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
rifampicin	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	O
:	O
64	O
%	O
were	O
Xpert	B:C0430022
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
rifampicin	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	O
:	O
64	O
%	O
were	O
Xpert	O
-	O
positive	B:C1446409
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
rifampicin	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	O
:	O
64	O
%	O
were	O
Xpert	O
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	B:C0035608
(	O
rifampicin	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	O
:	O
64	O
%	O
were	O
Xpert	O
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
rifampicin	B:C0035608
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	O
:	O
64	O
%	O
were	O
Xpert	O
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
rifampicin	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	B:C0679362
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	O
:	O
64	O
%	O
were	O
Xpert	O
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
rifampicin	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	B:C0679362
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	O
:	O
64	O
%	O
were	O
Xpert	O
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
rifampicin	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	B:C0041327
-	O
EPTB	O
.	O

Only	O
4	O
%	O
of	O
all	O
patients	O
were	O
tested	O
using	O
Xpert	O
:	O
64	O
%	O
were	O
Xpert	O
-	O
positive	O
,	O
13	O
%	O
showed	O
rifampicin	O
(	O
rifampicin	O
)	O
resistance	O
and	O
30	O
%	O
were	O
extrapulmonary	O
(	O
EPTB	O
)	O
or	O
both	O
pulmonary	O
-	O
EPTB	B:C0679362
.	O

Treatment	O
outcomes	O
were	O
mostly	O
favorable	O
(	O
77	O
%	O
)	O
and	O
we	O
found	O
little	O
association	O
between	O
Xpert	B:C0430022
use	O
and	O
an	O
unfavorable	O
tuberculosis	O
treatment	O
outcome	O
(	O
RR	O
1.25	O
,	O
95	O
%	O
CI	O
:	O
0.83	O
,	O
1.90	O
)	O
.	O

Treatment	O
outcomes	O
were	O
mostly	O
favorable	O
(	O
77	O
%	O
)	O
and	O
we	O
found	O
little	O
association	O
between	O
Xpert	O
use	O
and	O
an	O
unfavorable	O
tuberculosis	B:C0041296
treatment	O
outcome	O
(	O
RR	O
1.25	O
,	O
95	O
%	O
CI	O
:	O
0.83	O
,	O
1.90	O
)	O
.	O

In	O
this	O
cohort	B:C0599755
,	O
Xpert	O
utilization	O
was	O
low	O
even	O
though	O
the	O
majority	O
of	O
sites	O
had	O
access	O
to	O
the	O
test	O
.	O

In	O
this	O
cohort	O
,	O
Xpert	B:C0430022
utilization	O
was	O
low	O
even	O
though	O
the	O
majority	O
of	O
sites	O
had	O
access	O
to	O
the	O
test	O
.	O

In	O
this	O
cohort	O
,	O
Xpert	O
utilization	O
was	O
low	O
even	O
though	O
the	O
majority	O
of	O
sites	B:C0205145
had	O
access	O
to	O
the	O
test	O
.	O

In	O
this	O
cohort	O
,	O
Xpert	O
utilization	O
was	O
low	O
even	O
though	O
the	O
majority	O
of	O
sites	O
had	O
access	B:C0444454
to	O
the	O
test	O
.	O

In	O
this	O
cohort	O
,	O
Xpert	O
utilization	O
was	O
low	O
even	O
though	O
the	O
majority	O
of	O
sites	O
had	O
access	O
to	O
the	O
test	B:C0392366
.	O

Our	O
findings	B:C0243095
show	O
the	O
need	O
for	O
expanded	O
implementation	O
and	O
further	O
research	O
exploring	O
barriers	O
to	O
use	O
in	O
low	O
-	O
resource	O
settings	O
.	O

Our	O
findings	O
show	O
the	O
need	O
for	O
expanded	B:C0205229
implementation	O
and	O
further	O
research	O
exploring	O
barriers	O
to	O
use	O
in	O
low	O
-	O
resource	O
settings	O
.	O

Our	O
findings	O
show	O
the	O
need	O
for	O
expanded	O
implementation	O
and	O
further	O
research	B:C0035168
exploring	O
barriers	O
to	O
use	O
in	O
low	O
-	O
resource	O
settings	O
.	O

